本研究通过设置不同浓度梯度36%Baraca Forte悬浮剂(SC)田间小区药效试验,研究其对棉田杂草防除效果及安全性。试验结果表明:36%Baraca Forte SC 900 mL/hm^2处理用药后45 d杂草株防效、鲜重防效均在94%以上,36%Bacara Forte SC对棉田...本研究通过设置不同浓度梯度36%Baraca Forte悬浮剂(SC)田间小区药效试验,研究其对棉田杂草防除效果及安全性。试验结果表明:36%Baraca Forte SC 900 mL/hm^2处理用药后45 d杂草株防效、鲜重防效均在94%以上,36%Bacara Forte SC对棉田杂草有良好的防治效果,且对棉花安全,无药害。展开更多
BACKGROUND Liver cancer is among the top five most common cancers globally.Lipid-lowering drugs such as statins can lower the risk of liver cancer,but may also cause liver damage.LipoCol Forte capsules(LFC),a red yeas...BACKGROUND Liver cancer is among the top five most common cancers globally.Lipid-lowering drugs such as statins can lower the risk of liver cancer,but may also cause liver damage.LipoCol Forte capsules(LFC),a red yeast rice product,have demonstrated significant antihypercholesterolemic effects and a good safety profile in clinical studies.AIM To evaluate whether LFC lowers the risk of liver cancer in adults in this propensity score-matched,nationwide,population-based cohort study.METHODS We used data from Taiwan Health Insurance Research Database,China,which includes electronic medical records for up to 99.99%of Taiwan region of China’s population.LFC users and LFC non-users were matched 1:1 by propensity scores between January 2010 and December 2017.All had followup data for at least 1 year.Statistical analyses compared demographic distributions including sex,age,comorbidities,and prescribed medications.Cox regression analyses estimated adjusted hazard ratios(aHRs)after adjusting for potential confounders.RESULTS We enrolled 33231 LFC users and 33231 non-LFC users(controls).No significant differences between the study cohorts were identified regarding comorbidities and medications[standardized mean difference(SMD)<0.05].At follow-up,the overall incidence of liver cancer was significantly lower in the LFC cohort compared with controls[aHR 0.91;95%confidence interval(CI):0.86-0.95;P<0.001].The risk of liver cancer was significantly reduced in both females(aHR 0.87;95%CI:0.8-0.94;P<0.001)and males(aHR 0.93;95%CI:0.87-0.98;P<0.01)in the LFC cohort compared with their counterparts in the non-LFC cohort.The antitumor protective effects applied to patients with comorbidities(including hypertension,ischemic stroke,diabetes mellitus,hyperlipidemia,hepatitis B infection and hepatitis C infection).Those using LFC for more than 84 drug days had a 0.64-fold lower risk of liver cancer compared with controls(P<0.001).Compared with controls,the risk of developing liver cancer in the LFC cohort progressively decreased over time;the lowest incidence of liver cancer occurred in LFC users followed-up for more than 6 years(27.44 vs 31.49 per 1,000 person-years;aHR 0.75;95%CI:0.68-0.82;P<0.001).CONCLUSION This retrospective cohort study indicates that LFC has a significantly protective effect on lowering the risk of liver cancer,in a dose-dependent and time-dependent manner.展开更多
Background:Patients with neovascular age-related macular degeneration(nAMD)often have pathologically elevated homocysteine(Hcy)and increased retinal venous pressure(RVP).We tested whether the administration of a speci...Background:Patients with neovascular age-related macular degeneration(nAMD)often have pathologically elevated homocysteine(Hcy)and increased retinal venous pressure(RVP).We tested whether the administration of a specific vitamin preparation containing L-methylfolate(Ocufolin forte)as an addition to antivascular endothelial growth factor(anti-VEGF)therapy reduces these two risk factors and favorably influences the disease course.Methods:A total of 27 eyes/27 patients with intra-and subretinal fluid,Hcy above 12μmol/L,RVP of at least 8 mm above the intra-ocular pressure(IOP),and an IOP between 10 and 20 mmHg were included in this study.All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated.Fifteen patients additionally received one capsule of Ocufolin forte per day(Ocufolin group,OG),and the other twelve patients served as a control group(control group,CG).The following factors were measured before therapy and four months later:blood Hcy,best-corrected visual acuity(BCVA),IOP,RVP,optical coherence tomography(OCT),and optical coherence tomography-angiography(OCTA).Results:Hcy decreased on average by 5.58μmol/L in the OG and by 0.57μmol/L in the CG.The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG.The difference between the two groups was significant for both parameters(P<0.001);66%of the OG and 41%of the CG had no retinal fluid at the end of the study.After the completion of the study,the injection intervals could be extended more often in the OG patients than in the CG patients.Conclusions:When Ocufolin forte was added to the standard therapy,RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte.In addition,Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy.展开更多
肾动态显像GFR测定广泛应用于临床,静脉＂弹丸＂式注射质量是检测成功,结果可靠的基本保证。就静脉＂弹丸＂式注射质量,我科采用双肾及膀胱时间放射性曲线评价,方法简便、直观、易行,值得推广,现报告如下。1资料与方法（1）设备采用Phil...肾动态显像GFR测定广泛应用于临床,静脉＂弹丸＂式注射质量是检测成功,结果可靠的基本保证。就静脉＂弹丸＂式注射质量,我科采用双肾及膀胱时间放射性曲线评价,方法简便、直观、易行,值得推广,现报告如下。1资料与方法（1）设备采用Philips Forte SPECT,患者仰卧后位采集,视野包括双肾及膀胱,应用共行成像方法,展开更多
目的 探讨联合应用高位Le Fort Ⅰ型截骨同期牙槽嵴裂植骨矫治唇腭裂术后面中部畸形的可行性。方法2002年1月～2005年1月，共收治10例唇腭裂术后面中部畸形患者，男4例，女6例。年龄16～32岁。单侧唇腭裂8例，双侧2例。影像学检查均有...目的 探讨联合应用高位Le Fort Ⅰ型截骨同期牙槽嵴裂植骨矫治唇腭裂术后面中部畸形的可行性。方法2002年1月～2005年1月，共收治10例唇腭裂术后面中部畸形患者，男4例，女6例。年龄16～32岁。单侧唇腭裂8例，双侧2例。影像学检查均有继发面中部畸形的主要表现。均采用高位Le Fort Ⅰ型截骨和牙槽嵴裂自体髂骨游离移植一期手术矫正。高位Le Fort Ⅰ型截骨的截骨线在上颌骨前壁比常规Le Fort Ⅰ型截骨线高，最高可达眶下孔下5mm左右，水平截开至颧牙槽嵴处再弧形转向下后方。结果术后伤口均I期愈合。复查头部X线片，所有患者上颌骨位置均得到明显改善。随访6～24个月，牙弓外形良好，X线片示无明显骨质吸收，植骨区密度与周围接近。10例均获得满意面容，其中9例获得良好的牙骀关系。结论高位Le Fort Ⅰ型截骨术不仅可前移上颌骨，还可前移部分眶下区及整个鼻旁区和鼻底，更明显地改善畸形。同期行牙槽嵴裂自体髂骨游离移植，可减少手术次数、降低费用、获得理想效果，是矫治唇腭裂术后面中部继发畸形的一种有效方法。展开更多
目的:采用多片段Le Fort I型截骨术矫治严重牙颌面畸形,并为克服术后骨段固位不良之缺点自制一种腭侧固定夹板。方法:以该手术方法联合双侧下颌升支矢状劈开术（BSSRO）矫治上颌宽度不足伴上下颌其它严重畸形的患者19例。采用单纯多片...目的:采用多片段Le Fort I型截骨术矫治严重牙颌面畸形,并为克服术后骨段固位不良之缺点自制一种腭侧固定夹板。方法:以该手术方法联合双侧下颌升支矢状劈开术（BSSRO）矫治上颌宽度不足伴上下颌其它严重畸形的患者19例。采用单纯多片段Le FortI型截骨6例,联合BSSRO13例。19例中上颌两片段Le FortI型截骨12例,3片段7例。结果:术后随访16例,平均22.6m,66间距离平均扩宽7.3mm,33间平均扩宽3.9mm。无严重并发症及明显复发,咬合关系满意。结论:应用良好的腭侧固定夹板,采用多片段 Le FortI截骨联合BSSRO可一次满意矫治严重双颌畸形。展开更多
文摘本研究通过设置不同浓度梯度36%Baraca Forte悬浮剂(SC)田间小区药效试验,研究其对棉田杂草防除效果及安全性。试验结果表明:36%Baraca Forte SC 900 mL/hm^2处理用药后45 d杂草株防效、鲜重防效均在94%以上,36%Bacara Forte SC对棉田杂草有良好的防治效果,且对棉花安全,无药害。
基金China Medical University Hospital,No.DMR-111-013 and No.DMR-111-195
文摘BACKGROUND Liver cancer is among the top five most common cancers globally.Lipid-lowering drugs such as statins can lower the risk of liver cancer,but may also cause liver damage.LipoCol Forte capsules(LFC),a red yeast rice product,have demonstrated significant antihypercholesterolemic effects and a good safety profile in clinical studies.AIM To evaluate whether LFC lowers the risk of liver cancer in adults in this propensity score-matched,nationwide,population-based cohort study.METHODS We used data from Taiwan Health Insurance Research Database,China,which includes electronic medical records for up to 99.99%of Taiwan region of China’s population.LFC users and LFC non-users were matched 1:1 by propensity scores between January 2010 and December 2017.All had followup data for at least 1 year.Statistical analyses compared demographic distributions including sex,age,comorbidities,and prescribed medications.Cox regression analyses estimated adjusted hazard ratios(aHRs)after adjusting for potential confounders.RESULTS We enrolled 33231 LFC users and 33231 non-LFC users(controls).No significant differences between the study cohorts were identified regarding comorbidities and medications[standardized mean difference(SMD)<0.05].At follow-up,the overall incidence of liver cancer was significantly lower in the LFC cohort compared with controls[aHR 0.91;95%confidence interval(CI):0.86-0.95;P<0.001].The risk of liver cancer was significantly reduced in both females(aHR 0.87;95%CI:0.8-0.94;P<0.001)and males(aHR 0.93;95%CI:0.87-0.98;P<0.01)in the LFC cohort compared with their counterparts in the non-LFC cohort.The antitumor protective effects applied to patients with comorbidities(including hypertension,ischemic stroke,diabetes mellitus,hyperlipidemia,hepatitis B infection and hepatitis C infection).Those using LFC for more than 84 drug days had a 0.64-fold lower risk of liver cancer compared with controls(P<0.001).Compared with controls,the risk of developing liver cancer in the LFC cohort progressively decreased over time;the lowest incidence of liver cancer occurred in LFC users followed-up for more than 6 years(27.44 vs 31.49 per 1,000 person-years;aHR 0.75;95%CI:0.68-0.82;P<0.001).CONCLUSION This retrospective cohort study indicates that LFC has a significantly protective effect on lowering the risk of liver cancer,in a dose-dependent and time-dependent manner.
文摘Background:Patients with neovascular age-related macular degeneration(nAMD)often have pathologically elevated homocysteine(Hcy)and increased retinal venous pressure(RVP).We tested whether the administration of a specific vitamin preparation containing L-methylfolate(Ocufolin forte)as an addition to antivascular endothelial growth factor(anti-VEGF)therapy reduces these two risk factors and favorably influences the disease course.Methods:A total of 27 eyes/27 patients with intra-and subretinal fluid,Hcy above 12μmol/L,RVP of at least 8 mm above the intra-ocular pressure(IOP),and an IOP between 10 and 20 mmHg were included in this study.All eyes received three injections of 0.05 ml aflibercept at one-month intervals as clinically indicated.Fifteen patients additionally received one capsule of Ocufolin forte per day(Ocufolin group,OG),and the other twelve patients served as a control group(control group,CG).The following factors were measured before therapy and four months later:blood Hcy,best-corrected visual acuity(BCVA),IOP,RVP,optical coherence tomography(OCT),and optical coherence tomography-angiography(OCTA).Results:Hcy decreased on average by 5.58μmol/L in the OG and by 0.57μmol/L in the CG.The RVP decreased on average by 4.60 mmHg in the OG and by 0.75 mmHg in the CG.The difference between the two groups was significant for both parameters(P<0.001);66%of the OG and 41%of the CG had no retinal fluid at the end of the study.After the completion of the study,the injection intervals could be extended more often in the OG patients than in the CG patients.Conclusions:When Ocufolin forte was added to the standard therapy,RVP and Hcy were reduced to a significantly greater extent than without Ocufolin forte.In addition,Ocufolin had a positive influence on morphology and future treatment intervals with anti-VEGF therapy.
文摘肾动态显像GFR测定广泛应用于临床,静脉＂弹丸＂式注射质量是检测成功,结果可靠的基本保证。就静脉＂弹丸＂式注射质量,我科采用双肾及膀胱时间放射性曲线评价,方法简便、直观、易行,值得推广,现报告如下。1资料与方法（1）设备采用Philips Forte SPECT,患者仰卧后位采集,视野包括双肾及膀胱,应用共行成像方法,
文摘目的 探讨联合应用高位Le Fort Ⅰ型截骨同期牙槽嵴裂植骨矫治唇腭裂术后面中部畸形的可行性。方法2002年1月～2005年1月，共收治10例唇腭裂术后面中部畸形患者，男4例，女6例。年龄16～32岁。单侧唇腭裂8例，双侧2例。影像学检查均有继发面中部畸形的主要表现。均采用高位Le Fort Ⅰ型截骨和牙槽嵴裂自体髂骨游离移植一期手术矫正。高位Le Fort Ⅰ型截骨的截骨线在上颌骨前壁比常规Le Fort Ⅰ型截骨线高，最高可达眶下孔下5mm左右，水平截开至颧牙槽嵴处再弧形转向下后方。结果术后伤口均I期愈合。复查头部X线片，所有患者上颌骨位置均得到明显改善。随访6～24个月，牙弓外形良好，X线片示无明显骨质吸收，植骨区密度与周围接近。10例均获得满意面容，其中9例获得良好的牙骀关系。结论高位Le Fort Ⅰ型截骨术不仅可前移上颌骨，还可前移部分眶下区及整个鼻旁区和鼻底，更明显地改善畸形。同期行牙槽嵴裂自体髂骨游离移植，可减少手术次数、降低费用、获得理想效果，是矫治唇腭裂术后面中部继发畸形的一种有效方法。
文摘目的:采用多片段Le Fort I型截骨术矫治严重牙颌面畸形,并为克服术后骨段固位不良之缺点自制一种腭侧固定夹板。方法:以该手术方法联合双侧下颌升支矢状劈开术（BSSRO）矫治上颌宽度不足伴上下颌其它严重畸形的患者19例。采用单纯多片段Le FortI型截骨6例,联合BSSRO13例。19例中上颌两片段Le FortI型截骨12例,3片段7例。结果:术后随访16例,平均22.6m,66间距离平均扩宽7.3mm,33间平均扩宽3.9mm。无严重并发症及明显复发,咬合关系满意。结论:应用良好的腭侧固定夹板,采用多片段 Le FortI截骨联合BSSRO可一次满意矫治严重双颌畸形。
